The review encapsulates the comprehensive exploration of RNA interference technology's application in shrimp aquaculture, covering molecular intricacies, production methods, and practical applications. The emphasis is on exploring the stability and delivery of gene‐specific double‐stranded RNA, particularly through nanoencapsulation. This is because the susceptibility of dsRNA to degradation and limited cellular penetration, emphasising the need for effective delivery mechanisms. The review presents an in‐depth exploration of nanoparticles for the encapsulation and delivery of dsRNA, including virus‐like particles (VLPs), and non‐viral based nanoparticles such as liposomes, chitosan, and beta‐glucan. VLPs, derived from non‐infectious shrimp virus structures, exhibit biocompatibility and natural functionality, making them suitable carriers for dsRNA. The application of chitosan and its derivatives are explored for their efficacy in reducing viral infections in shrimp. Beta‐glucan particles are examined for their immunostimulant properties in shrimp aquaculture. The text emphasises the use of yeast‐based glucan particles for encapsulating dsRNA, showcasing their potential in preventing viral diseases in shrimp. The review introduces cautionary considerations for nanoparticle formulation, highlighting factors such as pH, organic solvents, metal ions, and environmental ribonuclease that can impact dsRNA stability during synthesis. In conclusion, the text discusses the potential economic worthiness and environmental risk assessment of dsRNA technology in shrimp aquaculture. While acknowledging successful applications in other environments, it underscores the need for regulatory approval and risk assessment for dsRNA‐based products in the aquaculture industry. The evaluation of dsRNA in real‐world shrimp farms is deemed necessary for commercial utilisation, taking into account income, expenses, safety, and environmental considerations.

Drug resistance and metastasis are two major obstacles to cancer chemotherapy. During metastasis, cancer cells can survive as floating cells in the blood or lymphatic circulatory system, due to the acquisition of resistance to anoikis—a programmed cell death activated by loss of extracellular matrix attachment. The anoikis-resistant lung cancer cells also develop drug resistance. In this study, paclitaxel-encapsulated PLGA-lipid hybrid nanoparticles (PLHNPs) were formulated by nanoprecipitation combined with self-assembly. The paclitaxel-PLHNPs had an average particle size of 103.0 ± 1.6 nm and a zeta potential value of −52.9 mV with the monodisperse distribution. Cytotoxicity of the nanoparticles was evaluated in A549 human lung cancer cells cultivated as floating cells under non-adherent conditions, compared with A549 attached cells. The floating cells exhibited anoikis resistance as shown by a lack of caspase-3 activation, in contrast to floating normal epithelial cells. Paclitaxel tolerance was evident in floating cells which had an IC₅₀ value of 418.56 nM, compared to an IC₅₀ value of 7.88 nM for attached cells. Paclitaxel-PLHNPs significantly reduced the IC₅₀ values in both attached cells (IC₅₀ value of 0.11 nM, 71.6-fold decrease) and floating cells (IC₅₀ value of 1.13 nM, 370.4-fold decrease). This report demonstrated the potential of PLHNPs to improve the efficacy of the chemotherapeutic drug paclitaxel, for eradicating anoikis-resistant lung cancer cells during metastasis.